Heart Failure With Reduced Ejection Fraction (HFrEF) Clinical Trial
Official title:
The Effectiveness of Collaborative Health Management Model on Heart Failure Patient Functional Status, Quality of Life, and Rehospitalization: Randomized Controlled Trial
The purpose of this study is to explore the effect of the collaborative health management model on the functional status, quality of life and rehospitalization rate of patients with heart failure. This is a three-year project. The first phase (introduction phase): A systematic literature review and meta-analysis of collaborative care and heart failure patients will be conducted, and relevant research results will be evaluated for the clinical benefits of heart failure patients, and empirical knowledge will be proposed as The basic holistic conclusions are supported by the research literature on the establishment of a collaborative health management model for heart failure (CHMM). The second stage (construction period): based on the results of systematic literature review and meta-analysis, adopt the CHMM model, design intervention measures, and conduct pilot studies to determine the safety and feasibility of the research, and review future research improvements Wherever possible, develop more complete intervention measures. The third stage (operation period): Randomized controlled trials were adopted, with random sampling and double-blind research design. In the cardiology ward of a regional teaching hospital in the south, 120 patients with heart failure who met the admission criteria were selected, and 60 patients were selected as control group. The group received routine care in the hospital, and 60 of the experimental group received interventions in the collaborative health management model. Data collection includes variables such as physiological indices, functional status, self-care behavior, quality of life, re-admission rate, medical cost. Instruments tools include Minnesota Heart Failure Quality of Life Questionnaire, European Heart Failure Self-care Behavior Scale after the intervention 1 month, 2 months, and 3 months.The intervention effect will be statistically verified and analyzed by GEE. It is hoped that this care model will be applied to the clinical care of patients with heart failure, and will be verified by clinical benefits, reduce symptom troubles, improve quality of life, and reduce medical costs.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 100 Years |
Eligibility | Inclusion Criteria: - ?Patients diagnosed as heart failure by specialists (NYHA ?-III); ?20 years of age or older; ?Patients with clear consciousness and no cognitive impairment and major diseases (such as cancer); ?Can communicate in Mandarin and Taiwanese; ? Those who can answer the questionnaire by themselves or with the assistance of a research assistant. Exclusion Criteria: - NIL |
Country | Name | City | State |
---|---|---|---|
Taiwan | Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital | Pingtung | Donggang Township |
Taiwan | Research team | Pingtung |
Lead Sponsor | Collaborator |
---|---|
Antai Medical Care Corperation Antai Tian-Sheng Memorial Hospital/ Department of Nursing/National Ta |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CHF functional status | NYHAClass ?~? | pre intervenation | |
Primary | CHF functional status | NYHAClass ?~? | post intervention 1 months | |
Primary | CHF functional status | NYHAClass ?~? | post intervention 2 months | |
Primary | CHF functional status | NYHAClass ?~? | post intervention 3 months | |
Primary | CHF quality of life | Minnesota living with heart failure questionnaire, MLHFQ | pre intervention | |
Primary | CHF quality of life | Minnesota living with heart failure questionnaire, MLHFQ | post intervention 1 months | |
Primary | CHF quality of life | Minnesota living with heart failure questionnaire, MLHFQ | post intervention 2 months | |
Primary | CHF quality of life | Minnesota living with heart failure questionnaire, MLHFQ | post intervention 3 months | |
Primary | CHF rehospitalization | Re-admission rate | pre intervention | |
Primary | CHF rehospitalization | Re-admission rate | post intervention 1 months | |
Primary | CHF rehospitalization | Re-admission rate | post intervention 2 months | |
Primary | CHF rehospitalization | Re-admission rate | post intervention 3 months | |
Primary | CHF Self care behaviour | Heart Failure Self-Care Behaviour Sacle, EHFScBS | pre intervention | |
Primary | CHF Self care behaviour | Heart Failure Self-Care Behaviour Sacle, EHFScBS | post intervention 1 months | |
Primary | CHF Self care behaviour | Heart Failure Self-Care Behaviour Sacle, EHFScBS | post intervention 2 months | |
Primary | CHF Self care behaviour | Heart Failure Self-Care Behaviour Sacle, EHFScBS | post intervention 3 months | |
Primary | CHF Depression | Beck Depression Inventory(BDI) | pre intervention | |
Primary | CHF Depression | Beck Depression Inventory(BDI) | post intervention 1 months | |
Primary | CHF Depression | Beck Depression Inventory(BDI) | post intervention 2 months | |
Primary | CHF Depression | Beck Depression Inventory(BDI) | post intervention 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05328752 -
Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
|
Phase 1 | |
Recruiting |
NCT05420012 -
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
|
Phase 4 | |
Active, not recruiting |
NCT05136820 -
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
|
N/A | |
Not yet recruiting |
NCT04304560 -
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
|
Phase 2 | |
Completed |
NCT04180696 -
Mid-Q Response Study
|
N/A | |
Recruiting |
NCT04331769 -
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
|
N/A | |
Completed |
NCT03877237 -
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
|
Phase 3 |